Strategy

Tapping Compliance Data to Drive Success

August 10, 2020

ByXavier Duburcq

How pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.

Strategic Realignment for a Better Future

July 21, 2020

ByBen van der Schaaf and Aurelien Guichard

In adjusting to the long-term side-effects of the coronavirus pandemic, pharma companies will need to focus on change in three areas. Ben van der Schaaf and Aurelien Guichard report.

Culture and Compliance: Building a Culture of Business Ethics

July 08, 2020

ByJohn F. Crowley|Patrik Florencio

Pharmaceutical Executive

Amid the limitations of traditional compliance programs that emphasize control measures, here are steps biopharma companies can implement in their own cultures to ensure they’re behaving and performing with integrity.

Pharma CEO Leadership During the Pandemic

July 06, 2020

ByPharmaceutical Executive Editors

Pharmaceutical Executive

A recent roundtable of pharmaceutical CEOs, and moderated by Dr. Scott Gottlieb, discussed pressing concerns around the pandemic, including clinical trials, product launches, keeping employees safe and the future of the pharmaceutical industry.

Research Reveals New Launch Standards for First-to-Launch Pharma and Biotech Companies in the U.S.

June 26, 2020

ByMaya Desai|Blake Beber|Eduardo Schur|Justin Zamirowski

While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.

Outlining Current and Future Trends in Medical Information

June 24, 2020

ByIrene Infanti|Mary Anne Greenberg

With the role of Medical Information in pharma companies changing in recent years, this article outlines some current and future trends including globalization and the use of data to drive change.

Medical Affairs and Medical Science Liaison (MSL) Board Certification: A Comprehensive Review

June 10, 2020

ByEric Bouilloux|Tina Kanmaz|Jill Massey

With the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.

Pricing for Rare Disease and Curative Therapies: What’s Fair?

June 02, 2020

ByAndrew Parece|Matthew Majewski|Kristen Backor|Joseph Black

There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.

The Myth of Skyrocketing Drug Prices: A Closer Look at The US Gross to Net Problem

June 01, 2020

ByChance Scott|Erik Sabot|Kathryne Kirk

While there has been an increase in discourse concerning drug pricing transparency in recent years, there is still a degree of misunderstanding. This is due to the healthcare industry's numerous stakeholders and their compelling interests. This research done by Guidehouse aims to clear the picture.

How Biosimilar Manufacturers Can Get the Most Out of the "Patent Cliff"

May 21, 2020

ByGeorge I’ons

As the number of biologics facing patent expiration in the US continues to rise, the market is further opening up to biosimilar manufacturers. George I'ons offers some pointers on how to secure an attractive market share during this time.